Hantz Financial Services Inc. Has $3.82 Million Stock Holdings in Sanofi $SNY

Hantz Financial Services Inc. boosted its position in shares of Sanofi (NASDAQ:SNY) by 43.1% in the third quarter, Holdings Channel reports. The firm owned 80,832 shares of the company’s stock after purchasing an additional 24,328 shares during the period. Hantz Financial Services Inc.’s holdings in Sanofi were worth $3,815,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of SNY. Raymond James Financial Inc. grew its holdings in shares of Sanofi by 81.3% in the 2nd quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after buying an additional 2,635,867 shares during the period. Franklin Resources Inc. lifted its holdings in Sanofi by 9.9% during the second quarter. Franklin Resources Inc. now owns 4,274,410 shares of the company’s stock worth $206,497,000 after acquiring an additional 384,902 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in Sanofi by 4.8% during the second quarter. Envestnet Asset Management Inc. now owns 3,434,999 shares of the company’s stock worth $165,945,000 after acquiring an additional 157,605 shares in the last quarter. Equity Investment Corp grew its stake in Sanofi by 2.5% in the second quarter. Equity Investment Corp now owns 2,512,435 shares of the company’s stock valued at $121,376,000 after acquiring an additional 62,109 shares during the period. Finally, Brandes Investment Partners LP increased its holdings in shares of Sanofi by 9.1% in the second quarter. Brandes Investment Partners LP now owns 2,483,767 shares of the company’s stock worth $119,992,000 after acquiring an additional 208,090 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SNY. Guggenheim cut Sanofi from a “buy” rating to a “neutral” rating in a report on Tuesday, December 9th. HSBC restated a “buy” rating on shares of Sanofi in a report on Wednesday, December 10th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Sanofi in a research note on Tuesday, December 30th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, Sanofi has an average rating of “Moderate Buy” and a consensus target price of $62.67.

Sanofi Stock Performance

Shares of SNY stock opened at $47.49 on Friday. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12. The company’s fifty day simple moving average is $47.95 and its 200-day simple moving average is $48.67. The firm has a market cap of $115.83 billion, a PE ratio of 13.19, a P/E/G ratio of 1.25 and a beta of 0.45. The company has a quick ratio of 0.29, a current ratio of 1.09 and a debt-to-equity ratio of 0.20.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.